The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for blockbuster treatments and impressive returns is clear, the associated risks are also considerable. Many of